A mechanism-led look at pruritus, its signaling pathways, and the active compounds formulated to address it.

Most of us have experienced it: an itch that seems to intensify the moment you scratch it, pulling you into a loop that feels impossible to break. We tend to dismiss itching as a minor inconvenience, but the underlying biology tells a more complex story—one that involves the nervous system, the immune system, and the skin barrier working in concert, and occasionally in conflict.

For formulators developing products for sensitive, reactive, or compromised skin, understanding that biology is not optional. It is the starting point for any claim that holds up to scrutiny.

What Is Pruritus—and Why Does Scratching Make It Worse?

Pruritus is defined in dermatological literature as an unpleasant cutaneous sensation arising from the stimulation of free nerve endings, typically at the dermal-epidermal junction, that elicits a desire to scratch.

The itch-scratch cycle has a neurochemical basis that researchers have been working to characterize for decades. Studies from the Center for the Study of Itch at Washington University School of Medicine have shed light on why scratching provides only temporary relief—and why it tends to perpetuate the sensation it is meant to relieve.

Scratching produces a brief analgesic effect by activating pain-signaling pathways, which temporarily override the itch signal. The brain responds to that pain stimulus by releasing serotonin—a modulatory neurotransmitter that, in this context, becomes part of the problem. Serotonin binds to receptors on neurons involved in itch transmission, effectively amplifying the itch signal rather than resolving it. The result: relief is short-lived, and the itch returns, often stronger than before.

This mechanism is worth understanding not because it is actionable at the formulation level directly, but because it frames the underlying challenge: itch is not a peripheral skin event. It is a signal that the central nervous system has been recruited into, and it involves neurochemical feedback loops that surface-level interventions alone cannot fully address.

Pruritus can also be triggered or worsened by systemic factors—including metabolic conditions, certain medications, and psychological stress—and by environmental conditions such as low ambient humidity. Cosmetic ingredient strategies, by definition, address the cutaneous component of this picture.

Three Mechanisms That Drive Skin Itch

Modern dermatological science identifies three primary, overlapping pathways through which pruritus is initiated and sustained:

1. Skin Barrier Disruption

The stratum corneum serves as the primary physical and chemical barrier between skin and the external environment. When that barrier is compromised—by surfactant exposure, environmental damage, atopic skin conditions, or chronic inflammation—a cascade of events follows.

Transepidermal water loss increases, leading to dryness and surface roughness. The lipid matrix between corneocytes becomes disorganized, allowing environmental irritants and potential allergens to penetrate more readily into deeper skin layers, where they come into contact with sensory nerve endings and immune cells. Dry skin itself generates mechanical friction at the nerve fiber level—a direct physical trigger for itch signals. And because barrier repair capacity is also compromised, the inflammatory response that follows tends to persist rather than resolve, sustaining the itch-scratch cycle.

2. Neural Sensitization

A population of specialized unmyelinated C-fiber neurons—sometimes called pruriceptors—have free endings throughout the epidermis and dermis. Under normal conditions, these neurons maintain a baseline threshold for itch signal transmission. Under sensitized conditions, that threshold drops significantly.

Several immune mediators are responsible for this sensitization. Allergens or bacterial products can activate Th2 helper T cells, which release cytokines including IL-31—a particularly potent pruritogenic signaling molecule. Th2 activity also triggers mast cell degranulation, releasing preformed and newly synthesized mediators including histamine, Substance P, and prostaglandins.

These mediators act on pruriceptor terminals, generating electrical signals that travel via the dorsal root ganglia to the spinal cord and on to the brain—where the experience of itch is consciously perceived. Chronic inflammation can also lead to nerve fiber proliferation and sensitization, a state in which even mild stimuli produce disproportionately intense itch responses.

3. Immune-Mediated Inflammation

When sensitizing or irritating substances penetrate the skin, antigen-presenting cells trigger an immune cascade. The resulting release of histamine, leukotrienes, and prostaglandins directly stimulates sensory nerve endings while increasing vascular permeability—producing the characteristic redness and swelling that accompanies inflammatory itch.

Histamine's role is particularly well-characterized: binding to H1 receptors on sensory nerve terminals generates neuronal impulses that are transmitted to the central nervous system, producing the subjective experience of itch. This is the mechanistic basis for the efficacy of antihistamines in allergic itch—though histamine-independent pathways (such as IL-31 signaling) explain why antihistamines are not universally effective across all itch presentations.

Active Ingredients Mapped to the Three Key Targets

Contemporary formulation strategy for skin sensitivity addresses three corresponding targets: barrier repair, reduction of neural receptor hyperreactivity, and interruption of the inflammatory cascade. The following summarizes ingredient categories that evidence supports for each.

Regulatory note: The ingredients and mechanisms described below relate to their potential to support skin appearance, comfort, and condition. These descriptions are intended for formulator and R&D audiences. Consumer-facing claims should reflect local regulatory frameworks—including EU Cosmetics Regulation No. 1223/2009, UK Cosmetic Products Regulation, and applicable FDA guidance—and should be positioned in terms of visible or perceivable cosmetic outcomes rather than physiological mechanisms.

Target 1: Supporting the Skin Barrier

These ingredients work to help restore the structural integrity of the stratum corneum, reduce transepidermal water loss, and reinforce the skin's physical defenses.

Shea butter has a well-established profile in barrier support, attributed to its fatty acid and triterpene content. Its occlusive and emollient properties help the skin maintain surface hydration and resist environmental challenge.

Coix seed oil (Coix lacryma-jobi) has demonstrated, in preclinical models, a capacity to help reduce markers of skin inflammation and surface disruption—making it a subject of growing interest in barrier repair formulations.

Astragalus polysaccharides, derived from a plant long used in traditional medicine, have been studied in wound healing and barrier recovery contexts, with findings suggesting activity in promoting tissue repair and moderating pro-inflammatory cytokine expression.

Target 2: Calming Neural Receptor Hyperreactivity

This is a mechanistically distinct area—focused not on the immune cascade but on the sensitized nerve fiber itself. The TRPV1 receptor (transient receptor potential vanilloid 1) is a key target here: a cation channel on sensory neurons that responds to heat, acidic pH, and chemical irritants, and whose overactivation is strongly associated with neurogenic itch and sensitive skin responses.

Pomelo (Citrus grandis) fruit extract has been studied for its capacity to modulate TRPV1 and related channel expression, with findings indicating a potential role in reducing itch-associated sensory signaling and skin discomfort—including the reactive sensitivity sometimes associated with high-potency active ingredients such as retinoids or vitamin C derivatives.

Target 3: Moderating the Inflammatory Response

These ingredients target the signaling cascade that produces and sustains inflammatory itch, with the goal of helping to reduce the visible and perceptible signs of skin reactivity.

Quercetin, soy isoflavones, and rutin are polyphenolic compounds found broadly in plant foods, with evidence for antioxidant activity and modulation of pro-inflammatory signaling pathways in skin-relevant models.

Licorice-derived compounds—including glabridin and dipotassium glycyrrhizinate—have a substantial body of literature behind them. Both have demonstrated anti-inflammatory and soothing activity in skin models, with dipotassium glycyrrhizinate in particular being widely used in formulations intended for reactive and sensitive skin types.

Nanohealth's Anti-Sensitivity Ingredient Platform

Nanohealth has developed a range of anti-sensitivity ingredients grounded in the three-target framework described above. The following are among the company's core offerings in this category:

Conclusion: Mechanism-Informed Formulation

Skin itching is not a surface event. It is the perceptible output of a multi-system process involving barrier integrity, immune cell activation, neural sensitization, and central nervous system feedback. Formulating effectively for sensitive or reactive skin requires engaging with at least some part of that process at the ingredient level—not simply masking the sensation.

The three-target model—repair the barrier, calm the sensitized nerve, interrupt the inflammatory cascade—provides a practical framework for both ingredient selection and formulation architecture. Ingredients with evidence across more than one of these targets offer particular value; combinations designed around complementary mechanisms can deliver outcomes that single-mechanism approaches cannot.

Understanding the why behind skin reactivity is, ultimately, what separates a well-designed sensitive skin formulation from a collection of soothing-adjacent claims.